` MTST (MetaStat Inc) vs S&P 500 Comparison - Alpha Spread

MTST
vs
S&P 500

Over the past 12 months, MTST has significantly outperformed S&P 500, delivering a return of +500% compared to the S&P 500's +16% growth.

Stocks Performance
MTST vs S&P 500

Loading
MTST
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MTST vs S&P 500

Loading
MTST
S&P 500
Difference
www.alphaspread.com

Performance By Year
MTST vs S&P 500

Loading
MTST
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
MetaStat Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

MetaStat Inc
Glance View

MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.

MTST Intrinsic Value
Not Available
Back to Top